Walleye Capital
FDMT icon

Walleye Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Walleye Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,762
Closed -$381K – 4577
2025
Q4 		$381K Buy
+50,762
New +$515K ﹤0.01% 3128
2024
Q4 		– Sell
-84,322
Closed -$912K – 5049
2024
Q3 		$912K Buy
+84,322
New +$1.4M ﹤0.01% 2747
2023
Q1 		– Sell
-16,919
Closed -$376K – 4056
2022
Q4 		$376K Buy
+16,919
New +$261K 0.01% 1640
2022
Q3 		– Sell
-28,068
Closed -$196K – 3312
2022
Q2 		$196K Buy
+28,068
New +$273K 0.01% 1530
2021
Q3 		– Sell
-12,205
Closed -$294K – 1660
2021
Q2 		$294K Buy
+12,205
New +$374K 0.01% 954

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Walleye Capital's FDMT Position: Q1 2026 in Review

Walleye Capital sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 50,762 shares — an estimated $381K sold.

Walleye Capital first reported a position in FDMT in Q2 2021 and held it in 5 quarters. The position peaked at $912K in Q3 2024. 153 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Walleye Capital reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 50,762 4D Molecular Therapeutics shares in Q1 2026, an estimated $381K.
  • Walleye Capital first reported a position in 4D Molecular Therapeutics in Q2 2021 and held it in 5 quarters.
  • Walleye Capital's 4D Molecular Therapeutics position peaked at $912K in Q3 2024.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.